Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Apr;94(4):E112-E115.
doi: 10.1002/ajh.25412. Epub 2019 Feb 6.

"Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemia

Titilola S Akingbola  1 , Bamidele O Tayo  2 , Chinedu A Ezekekwu  1 , Omowunmi Sonubi  1 , Xu Zhang  3 , Santosh L Saraf  3 , Robert Molokie  3   4 , Lewis L Hsu  5 , Jin Han  6 , Richard S Cooper  2 , Victor R Gordeuk  3
Affiliations
Clinical Trial

"Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemia

Titilola S Akingbola et al. Am J Hematol. 2019 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.. A. Effect of two starting doses of hydroxyurea on hematology measures.
Shown are mean and SD values for hemoglobin, MCV, neutrophils and platelets over the first 12 to 14 weeks of hydroxyurea treatment in the Multicenter Study of Hydroxyurea (MSH) cohort (14 weeks of treatment, 15 mg/kg/day, n=152)_ENREF 213 and the Ibadan cohort (12 weeks of treatment, 10 mg/kg/day, n=38). Changes from baseline were comparable between the two approaches in hemoglobin, MCV and platelets but the neutrophils had less of a decline in the Ibadan cohort. B. Effect of two approaches to hydroxyurea dosing on end of study values for hemoglobin F and hematology measures.At end of study, changes in hemoglobin F and other hematology measures were comparable between the MSH study, which targeted “maximum tolerated dose” hydroxyurea, and the Ibadan study, which administered 500 mg/day (10 mg/kg/day) as a “fixed low-dose” regimen. Hb F (hemoglobin F), HB (hemoglobin), HCT (hematocrit), MCV (mean corpuscular volume), WBC (white blood cells), ANC (neutrophils), PLT (platelets).
See this image and copyright information in PMC

Comment on

  • Am J Hematol.

References

    1. Stettler N, McKiernan CM, Melin CQ, Adejoro OO, Walczak NB. Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea. JAMA 2015;313:1671–2. - PubMed
    1. Tayo BO, Akingbola TS, Saraf SL, Shah BN, Ezekekwu CA, Sonubi O, Hsu LL, Cooper RS, Gordeuk VR. Fixed Low-Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Anemia in Nigeria. Am J Hematol 2018. - PMC - PubMed
    1. Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive “switching” agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore) 1996;75:300–26. - PubMed
    1. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317–22. - PubMed
    1. Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 2008;358:1362–9. - PubMed